Results 211 to 220 of about 361,864 (351)

Voclosporin‐induced gingival enlargement: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca, Jessica M. Greco, Dimitris N. Tatakis   +2 more
wiley   +1 more source

Two Cases of Lupus Erythematosus [PDF]

, 1909
Haldin Davis
openalex   +1 more source

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

Clinical Pharmacology &Therapeutics, EarlyView.
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as “slow acetylators”) are predicted to have increased plasma hydralazine concentrations compared with ...
Michael T. Eadon, David W. Hein, Michael A. Andersen, Arlene B. Chapman, Rhonda M. Cooper‐DeHoff, Zeruesenay Desta, Julio D. Duarte, Amanda L. Elchynski, Andrea Gaedigk, Seth E. Karol, Nita A. Limdi, Christelle Lteif, Laura Sosinski, Pablo Zubiaur, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Roseann S. Donnelly, José A.G. Agúndez   +18 more
wiley   +1 more source

Intensive Panthenol Therapy of Lupus Erythematosus*

, 1950
Leon Goldman
openalex   +1 more source

Case of Lupus Erythematosus [PDF]

, 1913
J. H. Sequeira
openalex   +1 more source

Lupus Erythematosus [PDF]

Proceedings of the Royal Society of Medicine, 1931
openaire   +2 more sources

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, EarlyView.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source

Tuberculosis in patients with systemic lupus erythematosus. [PDF]

Front Immunol
Ongarj J, Intapiboon P, Tanner R, Pinpathomrat N.   +3 more
europepmc   +1 more source

Treatment of Subacute and Chronic Discoid Lupus Erythematosus with Intensive Calcium Pantothenate Therapy11From the Hair Laboratory of the Department of Dermatology and Syphilology of the College of Medicine, University of Cincinnati.

, 1948
Leon Goldman
openalex   +1 more source

A Fast Path from Innovation to Safe and Effective Medicines

Clinical Pharmacology &Therapeutics, EarlyView.
Consistent progress in medicines development has allowed both for de novo treatment options and for the refinement of existing products that improve effectiveness or reduce harm. Nonetheless, unmet medical needs persist, particularly in rare diseases, pediatrics and underserved populations.
Peter Arlett, Falk Ehmann, Ralf Herold, Evdokia Korakianiti, Pierpaolo Moscariello, Liese Barbier, Iordanis Gravanis, Frank Pétavy, Emmanuel Cormier, Andrew Thomson, Spiros Vamvakas, Steffen Thirstrup   +11 more
wiley   +1 more source